Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Pegasys plus ribavirin treatment in difficult-to-treat treatment-naive chronic hepatitis C
ChiCTR-TRC-10000926Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of interferon alfa and ribavirin in hepatitis C virus infection (3 arms), sponsored by Peking University People's Hospital. Primary endpoints: Sustained virological response and Individual treatment. Started Apr 2009; status: completed.
02
Drugs
interferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on ChiCTR-TRC-10000926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000926.